Pluri Inc. Corporate Update
Pluri Inc. (ticker PLUR) experienced a 16.67 % increase in its share price during the 24‑hour period ending at 07:00 PM Central Europe on Thursday, 22 October 2026. The current trading price is approximately USD 1.07 per share on major exchanges.
- Outstanding shares: 12.6 million
- Market capitalization: USD 11.7 million
- Volume in last 24 hours: USD 52.6 k
- Year‑to‑date performance: down 4.55 % since the end of September 2026
- 200‑day simple moving average: USD 2.45
- 52‑week high: USD 4.87 (13 November 2025)
- 52‑week low: USD 0.85 (19 October 2026)
Recent Transaction
Pluri Inc. has entered into a securities purchase agreement with Chutzpah Holdings LP. The agreement, approved by the board, involves:
- Issuance of a block of common shares to Chutzpah Holdings LP.
- Issuance of a warrant allowing purchase of up to an equivalent number of shares at a set exercise price after a six‑month waiting period; the warrant expires five years from issuance.
- The transaction is exempt from registration requirements and is not a public offering.
- Share price will reflect the company’s recent valuation.
- Completion is contingent on regulatory and exchange approvals.
- Forward‑looking statements in the filing address potential completion and impact on shareholder value.
Related Stock Performance (Last 24 Hours)
| Symbol | Recent Movement | Current Price | Market Capitalisation |
|---|---|---|---|
| Way 2 Vat (W2V.AX) | -2.86 % | AUD 0.03 | AUD 10.6 million |
| Nutritional Growth (NGS.AX) | 0 % | AUD 0.02 | AUD 9.8 million |
| Pulsenmore (PLSM) | +1.14 % | USD 1.75 | USD 12.2 million |
| Innocan Pharma (INNPF) | -5 % | USD 1.33 | USD 6.0 million |
| Chemomab Therapeutics (CMMB) | -2.54 % | USD 1.06 | USD 8.4 million |
Additional Note on Pulsenmore
Pulsenmore Ltd. filed a Form 4 on 21 October 2026 reporting an option grant to its Chief Commercial Officer, David Woods. The grant covers 6,886 ordinary shares under a non‑qualified stock‑options plan, with an exercise price of approximately USD 2.50 per share. Vesting begins on 6 October 2027, expiring in 2033. No other ownership changes were disclosed.
Company Overview
Pluri Inc. is a biotechnology firm focused on mesenchymal stem cell production technology and the commercialization of cell therapies for disorders including severe blood diseases, cardiovascular conditions, autoimmune disorders, and other health issues. The company operates globally and is listed on the Nasdaq stock exchange. Further information is available at www.pluri-biotech.com .
